![]()
|
|
||||||||
(Received for publication, April 3, 1996, and in revised form, May 20, 1996)
From the Department of Biology, University of California, San
Diego, La Jolla, California 92093
We describe the isolation of a novel protein from
the conditioned medium of human articular cartilage chondrocytes in
primary culture. This 39-kDa protein has the N-terminal sequence YKL,
which we have termed YKL-39. The 1434-nucleotide sequence of the YKL-39
cDNA predicts a 385-residue initial translation product and a
364-residue mature YKL-39. The amino acid sequence of YKL-39 is most
closely related to YKL-40, followed by macrophage chitotriosidase,
oviductal glycoprotein, and macrophage YM-1. All five proteins share
significant sequence identity with bacterial chitinases and have the
probable structure of an ( In this study we report the discovery of a new member of the
mammalian protein family related in sequence to bacterial chitinases.
This protein family has an ( YKL-40 is a 40-kDa glycoprotein that was first discovered as a
heparin-binding protein secreted from bovine breast tissue during the
massive tissue involution that follows the cessation of lactation (7).
YKL-40 was subsequently discovered as a heparin-binding protein in the
conditioned medium of human synoviocytes (8), chondrocytes (4, 9), and
the MG-63 osteosarcoma cell line (10). YKL-40 has also been discovered
as a heparin-binding protein expressed by porcine vascular smooth
muscle cells undergoing a differentiation transition (11) and as a
protein expressed selectively by murine mammary tumors initiated by
neu/ras oncogenes (12). The present studies were
initiated to further examine the expression of YKL-40 by human
articular cartilage chondrocytes in culture. In the course of these
studies YKL-39 was found as a protein that copurified with YKL-40.
We report here the discovery, purification, characterization, and
sequence of human YKL-39.
Chondrocytes and synoviocytes were obtained from
Martin Lotz, director of the University of California, San Diego
osteoarthritis cell culture facility and were isolated and cultured
essentially as described (13). Cartilage from the femoral condyles and
tibial plateaus of the knee joints was obtained at autopsy from donors
without known history of joint disease or from healthy organ donors
from the University of California, San Diego tissue bank. Cartilage
slices were cut into pieces (2-3 mm3), washed with
DMEM,1 and treated for 15 min with trypsin
(10% v/v) in a 37 °C water bath. The tissues were transferred to
DMEM containing 5% fetal calf serum,
penicillin-streptomycin-Fungizone, and 2 mg/ml clostridial collagenase
type IV (Sigma) and digested overnight on a shaker
until the tissue fragments were dissolved. The cells were washed three
times with DMEM and cultured in T175 flasks containing 30 ml of DMEM
plus 10% fetal calf serum until confluent. All experiments reported
here used chondrocytes in primary culture or at passage 1 following a
1:3 subculture. To harvest conditioned culture medium, chondrocyte
cultures were grown to confluence in T175 flasks, washed twice with 30 ml of phosphate-buffered saline, and cultured in 30 ml of serum-free
DMEM for 1 week.
Synovial tissues were obtained from knee joints and washed with DMEM,
minced, and treated with trypsin (10% v/v) for 15 min in a 37 °C
water bath. The tissue fragments were then transferred to DMEM
containing 5% fetal calf serum, penicillin-streptomycin-Fungizone, and
2 mg/ml clostridial collagenase type IV (Sigma) and
digested on a shaker until dissolution of the fragments (about 3 h). The cells were washed three times with DMEM and cultured in T175
flasks. After 24 h nonadherent cells were removed, and the
adherent synovial cells were further cultured until confluent and then
harvested for RNA isolation.
To fractionate conditioned medium
proteins by size (see Fig. 1), 200 ml of medium obtained after 1 week
of culture in serum-free conditions was concentrated to 5 ml by
ultrafiltration using a 10-kDa MWCO membrane and applied to a 2 × 150-cm Sephacryl S-300 HR column equilibrated with 150 mM
NH4HCO3 at room temperature. To remove YKL-40
and other heparin-binding proteins, 600 ml of conditioned medium was
passed through a 2 × 15-cm heparin-Sepharose CL-6B column
initially equilibrated with 20 mM sodium phosphate buffer,
pH 7.4. The unbound proteins were concentrated to 5 ml by
ultrafiltration and then applied to a 2 × 150-cm Sephacryl S-300
HR column equilibrated with 150 mM
NH4HCO3 at room temperature (see Fig. 2).
SDS-polyacrylamide gel electrophoresis was
performed under reducing conditions using 4-20% gradient gels (Novex,
San Diego, CA) and stained with Coomassie Brilliant Blue or with the
periodic acid-Schiff reaction (glycoprotein detection kit,
Sigma). Conditioned medium was obtained from primary
chondrocytes cultured in the absence of serum for 7 days and was
dialyzed against milli Q water before concentration for electrophoresis
(see Fig. 1, inset, lane 2).
Purified proteins were
transferred to polyvinylidene difluoride membranes using a ProSpin
device (Applied Biosystems, Foster City, CA) and sequenced using a
Perkin-Elmer/Applied Biosystems Division model 494 sequenator equipped
with online high performance liquid chromatography.
As explained under
``Results,'' clone 118809 isolated by the Washington University-Merck
EST Project from a human lung cDNA library proved to be a cDNA
clone of YKL-39. We purchased this clone from Genome Systems, Inc. (St.
Louis, MO). SmaI and XhoI digestion of this clone
showed that it contains a 1.5-kilobase insert. We sequenced the 5 Total RNA was isolated from
chondrocytes, synoviocytes, MG-63 osteosarcoma cells, normal dermal
fibroblasts, and Hep G2 liver cells with an RNA STAT-60TM
kit (Tel-Test ``B,'' Inc., Friendswood, TX). Thirty µg of total RNA
from each cell line was fractionated on 1% formaldehyde-agarose gel in
4-morpholinepropanesulfonic acid buffer and transferred onto a Hybond-N
membrane (Amersham Corp.). A multiple tissue Northern blot containing
total RNA from human heart, brain, kidney, liver, lung, pancreas, and
spleen was purchased from BioChain Institute, Inc. (San Leandro, CA).
Following prehybridization for 3 h in 50% formamide, 5 × SSC, 5 × Denhardt's solution, and 100 µg/ml denatured salmon
sperm DNA at 42 °C, blots were hybridized with random primed
32P-labeled cDNA probes for 16-20 h under identical
conditions. Filters were washed three times for 1 h each with
0.1 × SSC containing 0.1% SDS at 65 °C and then exposed to
x-ray film. The blots were first hybridized with the EcoRI
fragment of clone 118809 (nucleotides 388-1256, see Fig. 4) and after
exposure to x-ray film were then stripped by boiling in H2O
containing 0.5% SDS and rehybridized with cDNA probes for YKL-40
(nucleotides 135-916, see Ref. 4) and glyceraldehyde-3-phosphate
dehydrogenase.
The chitinase activity
of YKL-39 was tested with the fluorogenic substrates
4-methylumbelliferyl
To harvest proteins secreted from
chondrocytes, primary cultures of human articular cartilage
chondrocytes were grown to confluence in media containing 10% fetal
calf serum and then switched to serum-free medium. After 1 week of
culture, conditioned medium was concentrated by ultrafiltration and
fractionated by molecular weight using Sephacryl S-300 HR. As seen in
Fig. 1, the major protein component in conditioned
medium emerges in an asymmetric peak centered at fraction 79. Fraction 79 gave a band2 at 40 kDa
upon SDS-PAGE (Fig. 1, inset) and proved to be YKL-40
by the criteria of N-terminal protein sequencing
(YKLVXYYTSW-) and by radioimmunoassay (9). The next most
abundant protein component in chondrocyte-conditioned medium emerges in
an asymmetric peak centered at fraction 70. N-terminal protein
sequencing of fraction 70 identified a major sequence identical to
human prostromelysin and a minor sequence identical to bovine serum
albumin. (The presence of some bovine albumin in conditioned medium is
not unusual in such experiments, since albumin is the most abundant
protein in fetal calf serum and so is the most likely serum constituent
to contaminate serum-free conditioned medium.)
Several experiments were carried out to ascertain the cause of the
asymmetry in the YKL-40 peak centered at fraction 79 in Fig. 1. When
the level of YKL-40 was determined by radioimmunoassay (9), there was a
good correlation between A220 and
immunoreactivity for fractions 77-80 but less immunoreactivity than
expected based on absorbance for fractions 81-84 (data not shown).
This result indicated the possible presence of an
A220-absorbing protein constituent not
recognized by the radioimmunoassay for YKL-40. SDS-PAGE of fraction 83 revealed a doublet at 39-40 kDa (Fig. 1, inset). N-terminal
protein sequencing of fraction 83 revealed the apparent presence of two
sequences, and therefore two proteins, each in approximately equimolar
amounts. One sequence is that of YKL-40
(YKLVXY To further evaluate the possible existence of a putative YKL-40-related
protein, another portion of the serum-free conditioned medium whose
fractionation is shown in Fig. 1 was separated by SDS-PAGE (Fig. 1,
inset) and transferred to a polyvinylidene difluoride
membrane. Subsequent N-terminal protein sequencing of the intense
protein band centered at 40 kDa revealed a mixture of two sequences,
the major (90%) of which is identical to YKL-40 and the minor (10%)
of which is identical to the putative YKL-40-related protein.
Interestingly, the N-terminal sequencing of YKL-40 purified from
conditioned medium by heparin affinity chromatography, our customary
procedure for purification of the protein (9), yielded only the
expected sequence of YKL-40 with no trace of the putative
YKL-40-related protein.
To see whether the putative YKL-40-related protein might be among the
conditioned medium proteins that did not bind to the heparin column,
the unbound protein fraction was concentrated by ultrafiltration and
fractionated by molecular weight using the same Sephacryl S-300 HR
column. As can be seen in Fig. 2, there is a protein
constituent at the approximate elution volume of YKL-40 centered at
effluent fraction 91. N-terminal protein sequencing of fraction 91 revealed the presence of a single sequence,
YKLVXYFTNWSQDRQEPGKFTPENI-, the sequence predicted for the
YKL-40-related protein, with no trace of the YKL-40 sequence itself.
SDS gel electrophoresis revealed this protein to be 39 kDa in apparent
mass and therefore slightly smaller than YKL-40 (Fig.
3a), and staining of the gel for carbohydrate
showed that the YKL-40-related protein is not a glycoprotein, whereas,
as previous studies have shown (4, 7), YKL-40 itself is (Fig.
3b). Since YKL-40 and the YKL-40-related protein have the
same N-terminal sequence YKL but differ in apparent mass, we have given
the YKL-40-related protein the provisional name YKL-39 to denote its
39-kDa apparent mass and so distinguish it from the 40-kDa YKL-40. The
other major protein component seen in the chromatogram shown in Fig. 2
emerges in an asymmetric peak centered at fraction 76. N-terminal
protein sequencing of fraction 76 revealed it to be a mixture of human
prostromelysin and bovine albumin.
Based on the recovery of A220 absorbance, a
direct measure of total protein, we calculate from the data in Figs. 1
and 2 that 10 confluent T175 flasks of articular cartilage chondrocytes
accumulate 18 mg of total protein (assuming a 1 mg/ml protein
concentration has an A220 = 10.0) into
conditioned medium after 1 week of culture in serum-free conditions. Of
this total, YKL-40 accounts for 6 mg (33% of total protein) and YKL-39
accounts for 0.75 mg (4%). The five fractions in Fig. 1 that contain
almost all of the prostromelysin (fractions 69-73; based on SDS-PAGE)
account for 3 mg of the conditioned medium protein (17%). Because
these fractions are contaminated with albumin, the actual amount of
prostromelysin in conditioned medium must be somewhat lower.
Before initiating
efforts to clone YKL-39 we investigated the possibility that clones for
YKL-39 may have already been partially sequenced as part of the
Washington University-Merck EST Project. One approach was to design a
predicted cDNA sequence from the N-terminal 25-residue sequence of
YKL-39 using where possible the preferred codon usage in humans. When
we used this to screen the EST data base with the Blast N program (15),
only one sequence gave a significant match, clone 257753 (GenBankTM/EBI accession number N40107[GenBank]). The other approach
was to use the known cDNA sequence of YKL-40 itself to identify
sequences closely related to, but not identical with, YKL-40. This
approach yielded an additional clone, clone 118809 (GenBankTM/EBI accession number T91693[GenBank]). The partial
sequences for clones 257753 and 118809 that were available in the EST
data base indicated a region of overlap identity, and we therefore
concluded that they were clones of the same gene. We then obtained
clone 118809 and determined its complete cDNA sequence.
Fig. 4 shows the complete nucleotide sequence of clone
118809 and the deduced amino acid sequence of YKL-39. The coding region
of YKL-39 is terminated by a TGA triplet at nucleotide 1191 and is
followed by 242 nucleotides of 3 The putative NXS site of N-glycosylation in
YKL-40, asparagine residue 60 and serine residue 62 (4), is not found
in YKL-39. There is a single potential recognition site for
N-glycosylation in YKL-39, the NWS sequence at residues 30 to 32. This site does not appear to be a functional site of
N-glycosylation in YKL-39 secreted from chondrocytes,
however, since no carbohydrate could be detected in purified YKL-39
(Fig. 3b) and N-terminal sequencing of the mature YKL-39
revealed the expected repetitive yield of asparagine at residue 9. Although the predicted number of amino acid residues in the mature form
of YKL-39 is slightly larger than for YKL-40 (364 versus 362 residues), the presence of carbohydrate in YKL-40 but not in YKL-39 is
probably sufficient to account for the fact that YKL-40 appears to be
slightly larger than YKL-39 based on its elution position from
Sephacryl S-300 HR (Fig. 1) and on its apparent SDS-PAGE molecular
weight (Fig. 3).
Five cell cultures were tested for the production of
YKL-39 by Northern blot. The 32P-labeled cDNA probe for
YKL-39 hybridized with a single 1.5-kilobase band in the chondrocyte
and synoviocyte RNA samples (Fig. 5a). This
size is in good agreement with the 1434-base pair size of clone 118809. No YKL-39 mRNA could be detected in RNA from normal human
fibroblasts, the HEP G2 human liver cell line, and the MG-63 human
osteoblastic osteosarcoma cell line. As expected (4, 10), reprobe of
this membrane demonstrated high levels of YKL-40 mRNA in
chondrocytes and MG-63 cells, lower levels in synoviocytes, and
undetectable levels in HEP G2 and fibroblasts (data not shown). The
lack of YKL-39 mRNA expression by MG-63 cells is in agreement with
the fact that the previously reported N-terminal protein sequencing of
the 40-kDa protein band seen in SDS-PAGE of MG63 conditioned media
identified the sequence of YKL-40 but failed to detect evidence of the
sequence of YKL-39 (10).
It is possible that culture under the serum-free conditions that are
needed for protein isolation from conditioned medium could
significantly alter the quantitative pattern of secreted protein
expression. To evaluate the possible effect of serum-free conditions on
YKL-39 expression, confluent primary chondrocytes were cultured for 1 week in serum-free medium or in medium containing 10% fetal calf
serum, and the level of YKL-39 was determined by Northern blot. The
YKL-39 levels in the serum-free and serum-containing cultures proved to
be identical (data not shown). We could also detect no effect of
serum-free conditions on the level of YKL-40 mRNA or on the medium
levels of YKL-40 antigen.
Seven tissues from adult humans were examined for the presence of
YKL-39 mRNA (Fig. 5b). YKL-39 mRNA is expressed
strongly in lung and is detectable in heart. No YKL-39 mRNA could
be detected in brain, spleen, pancreas, or liver. A reprobe of this
membrane failed to detect YKL-40 mRNA in any of these tissues.
Further evidence on the tissue distribution of YKL-39 mRNA
expression is provided by the frequency with which YKL-39 cDNA
clones have been identified by the Washington University-Merck EST
Project. Two different clones have been obtained from a human lung
cDNA library (GenBankTM/EBI accession numbers T91693[GenBank]
and T66009[GenBank]), one clone has been obtained from each of two infant brain
libraries (GenBankTM/EBI accession numbers H10721[GenBank] and
H10989[GenBank]), and one has been obtained from a placenta library
(GenBankTM/EBI accession number N40107[GenBank]). This evidence
suggests that YKL-39 may also be expressed in developing brain and in
placenta.
Pairwise
comparison of YKL-39 with the four previously identified mammalian
members of the protein family related in sequence to bacterial
chitinases using the ALIGN program (Protein Identification Resource)
shows that YKL-39 is most closely related to human YKL-40 (4) followed
by human chitotriosidase (3), human oviductal glycoprotein (6), and
murine YM-1 (GenBankTM/EBI accession number M94584[GenBank]). The
regions of sequence identity encompass all of YKL-39, YKL-40, and YM-1
and the N-terminal domains of chitotriosidase and of oviductal
glycoprotein. The C-terminal domain of chitotriosidase is related to
the C-terminal domain of nematode and insect chitinases (3) and has no
counterpart in YKL-40, YKL-39, or YM-1. The C-terminal domain of
oviductal glycoprotein is thought to be a region of extensive protein
glycosylation (6).
The amino acid sequence of YKL-39 is compared to the two proteins which
are most closely related to it in sequence, YKL-40 and chitotriosidase,
in Fig. 6. As can be seen, there is extensive sequence
identity among all three human proteins, particularly in the regions
that are thought to be involved in substrate binding in the bacterial
chitinases (18, 19) (Fig. 6, shaded residues). It is of
interest to note that the glutamate residue which is known from
mutagenesis studies to be essential for the activity of bacterial
chitinases (20) is found in chitotriosidase (Fig. 6, glutamate 139) but
not in YKL-39, YKL-40, YM-1, or oviductal glycoprotein. This
observation is consistent with the fact that chitotriosidase is a
glycosidic bound hydrolyase, while no enzymatic activity has yet been
reported for YKL-40, YM-1, or oviductal glycoprotein. Although we have
not carried out extensive tests of the possible enzymatic activities of
YKL-39, we did examine its possible chitinase activity (see
``Materials and Methods''). YKL-39 was not active in any of the four
assays tested (data not shown).
The high degree of sequence identity between YKL-40 and YKL-39, which
includes continuous stretches of identity up to 10 residues in length,
suggests that antibodies against one protein could cross-react with the
other. We therefore tested the possible cross-reactivity of YKL-39 on
the radioimmunoassay that we developed for measurement of human YKL-40
in serum and tissues (9). No cross-reactivity was observed, which
indicates that the dominant epitope recognized by the antiserum used
for the YKL-40 assay does not recognize YKL-39. It should be noted,
however, that this result does not rule out the presence of minor
cross-reacting antibodies in this antiserum.
Recent investigations have assigned bacterial chitinases and the
related mammalian proteins to a gene family termed family 18 of the
glycosylhydrolyses (1). Based on the crystallographic structure of one
member of this family, it has been further suggested that all members
of this gene family have the tertiary structure of an
( We speculate that the high level of sequence identity between
chitinases and YKL-39 in the region of the sequence that corresponds to
the putative chitinase active site (Fig. 6, shaded residues)
is best explained by the need to conserve residues involved in glycan
binding and that YKL-39 is likely to bind a given glycan structure with
high specificity. This hypothesis is supported by the fact that YKL-40
binds a glycan, heparin, with an affinity greater than found for the
well established heparin binding of fibronectin (11). Since YKL-39
clearly has no affinity for heparin in spite of its similarity in net
charge and sequence to YKL-40, it seems likely that heparin binding is
attributable to a specific binding site on YKL-40, one that is
conserved in all species tested (cow, human, pig). We are currently
investigating the glycan binding specificities of YKL-39.
We think
that the expression of YKL-39 at high levels in primary chondrocyte
cultures suggests that the protein could function in tissue remodeling
processes. Evidence for this hypothesis is provided by the identity of
the other major proteins in chondrocyte-conditioned medium (Fig. 1).
The most abundant protein in chondrocyte-conditioned medium, YKL-40, is
thought to be involved in remodeling of breast tissue (7), vascular
smooth muscle (11), and cartilage (4). YKL-40 is not in fact even
expressed at detectable levels in normal cartilage or in cartilage
explants until 2 days in culture (4) (data not shown). YKL-40 is,
however, expressed at high levels in arthritic cartilage, an abnormal
tissue characterized by high levels of tissue destruction and turnover.
The next most abundant protein in chondrocyte-conditioned medium,
prostromelysin, is an enzyme with broad substrate specificity which is
involved with the digestion of a wide variety of extracellular matrix
proteins in tissue remodeling processes. If YKL-39 is involved in the
remodeling of cartilage, it is likely that YKL-39 is, like YKL-40, not
expressed by normal cartilage but is induced in explant culture and
expressed at high levels in arthritic cartilage.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U49835[GenBank].
Volume 271, Number 32,
Issue of August 9, 1996
pp. 19415-19420
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.


)8 barrel. YKL-39 lacks the
active site glutamate, which is essential for the activity of
chitinases, and as expected has no chitinase activity. The highest
level of YKL-39 mRNA expression is seen in chondrocytes, followed
by synoviocytes, lung, and heart. YKL-39 accounts for 4% of the
protein in chondrocyte-conditioned medium, prostromelysin accounts for
17%, and YKL-40 accounts for 33%. In contrast to YKL-40, YKL-39 is
not a glycoprotein and does not bind to heparin.

)8 barrel structure (1,
2) and includes a protein secreted from human macrophages that does
have chitinase activity, which is termed chitotriosidase (3), and three
proteins with no presently known enzymatic activity, YKL-40 (4), YM-1
(GenBankTM/EBI accession number M94584[GenBank]), and oviductal
glycoprotein (6). Because the new member of this family, which we have
termed YKL-39, is more closely related in size and sequence to YKL-40
than to other members of this family, it is useful to summarize
research on YKL-40 as a background for the present investigation.
Isolation and Culture of Chondrocytes and
Synoviocytes
Fig. 1.
Separation of proteins in
chondrocyte-conditioned medium by filtration over a Sephacryl S-300 HR
column. Human articular cartilage chondrocytes were grown to
confluence and then changed to serum-free medium. After 7 days of
culture in serum-free conditions, 200 ml of medium was removed,
concentrated to 5 ml by ultrafiltration, and applied to a 2 × 150-cm Sephacryl S-300 HR column equilibrated with 150 mM
NH4HCO3 at room temperature. Fraction volume,
4.8 ml (see ``Materials and Methods'' for details). Inset,
SDS-polyacrylamide gel electrophoresis of fractions from the Sephacryl
S-300 HR column. Proteins were electrophoresed on a 4-20% gradient
gel and stained with Coomassie Brilliant Blue. Lane 1,
molecular mass standards; lane 2, 0.5 ml of
chondrocyte-conditioned medium; lane 3, 10 µg of fraction
70; lane 4, 10 µg of fraction 79; lane 5, 10 µg of fraction 83.
Fig. 2.
Purification of YKL-39 by filtration over
Sephacryl S-300 HR of the conditioned medium proteins that do not bind
heparin. 600 ml of 7-day conditioned medium (Fig. 1) were first
passed over a 2 × 30-cm column of heparin-Sepharose CL-6B to
remove YKL-40 and other heparin-binding proteins. The unbound fraction
was concentrated to 5 ml and applied to a 2 × 150-cm Sephacryl
S-300 HR column equilibrated with 150 mM
NH4HCO3 at room temperature. Fraction volume,
4.2 ml (see ``Materials and Methods'' for details).
and
3
ends of the insert DNA using a T7 primer and a M13 reverse primer
for the pBluescript SK(
) phagemid and a version 2.0 DNA sequencing
kit (U. S. Biochemical Corp.). Synthetic primers were synthesized from
the DNA sequences and used to extend the sequence in increments until
the sequence of both strands was determined.
Fig. 4.
Complete nucleotide sequence of YKL-39
cDNA and deduced amino acid sequence of the protein. The
underlined sequence corresponds to that determined by
N-terminal protein sequencing. The cleavage site of the putative signal
sequence is indicated by the arrow after residue 21, and the
N terminus of mature YKL-39 begins at residue 22. The stop codon is
marked by asterisks, and the polyadenylation signal sequence
AATAAA is indicated by boldface.
-D-N,N
-diacetylchitobiose and
4-methylumbelliferyl
-D-N,N
,N"-triacetylchitotriose
(Sigma), and the p-nitrophenyl substrates
p-nitrophenyl
-D-N,N
-diacetylchitobiose and
p-nitrophenyl
-D-N,N
,N
-triacetylchitotriose
(Sigma), as described by Renkema et al.
(14). Chitinase from Serratia marcescens
(Sigma) was used as a positive control.
Purification of Cousin
T
WSQ
R-)
and the other is very similar to YKL-40
(YKLVXY
T
WSQ
R-).
Fig. 3.
SDS-PAGE comparison of YKL-39 and
YKL-40. Proteins were electrophoresed on a 4-20% gradient gel
and stained with Coomassie Brilliant Blue (a) and the
Sigma glycoprotein detection kit (b).
Lane MW, molecular mass standards; lanes 1a
and 1b, 5 and 10 µg of YKL-40; lanes 2a
and 2b, 5 and 10 µg of YKL-39.
-untranslated region with a potential
polyadenylation signal (AATAAA) at nucleotides 1391-1396. The ATG,
found at nucleotides 36-38, was considered to be the initiation codon
according to the rules for translation initiation described previously
(16). The open reading frame codes for a 385-residue-long protein
containing a 21-residue transmembrane signal peptide with a potential
signal peptidase cleavage site at amino acid residue 21 (17). The
predicted protein, after removal of the signal peptide, has a length of
364 amino acids and a calculated molecular mass of 40,825 Da. The
predicted N-terminal sequence of YKL-39 is identical to the N-terminal
25-residue sequence determined by protein sequencing of the purified
protein.
Fig. 5.
Northern blot analysis of YKL-39 message
levels in human cell lines and human tissues. a, 30 µg of
total RNA from chondrocytes (lane 1), synoviocytes
(lane 2), MG-63 osteosarcoma cells (lane 3),
normal dermal fibroblasts (lane 4), and Hep G2 liver cells
(lane 5) were run on a 1% formaldehyde-agarose gel and
blotted onto a Hybond-N membrane. b, a commercially obtained
human multiple tissue blot containing 20 µg of total RNA from human
heart (lane 1), brain (lane 2), kidney
(lane 3), liver (lane 4), lung (lane
5), pancreas (lane 6), and spleen (lane 7).
The blots were first hybridized with a 32P-labeled YKL-39
cDNA probe and then reprobed with a 32P-labeled
glyceraldehyde-3-phosphate dehydrogenase cDNA fragment.
Comparison of YKL-39 to Related Mammalian Proteins
Fig. 6.
Alignment of YKL-39 with mammalian members of
the chitinase protein family. The sequences of human YKL-39 (Fig.
5), human YKL-40 (4), and human chitotriosidase (3) are compared
starting with the first residue of the initial translation product.
Identical amino acids are boxed. The shaded
residues indicate the sequence regions that correspond to the
putative active site in bacterial chitinases (18, 19).

)8 barrel (also called a TIM barrel) (2). TIM
barrels are the most common architecture of enzymes and are found in
10% of the enzymes whose structures are presently known (21). The
substrate binding site in such enzymes is invariably formed by the
loops which connect the
sheet and
helical segments that are
located at the C-terminal end of the 8-stranded barrel. It seems
probable that this region of the YKL-39 structure also has specific
binding properties, forming either an active site or a specific glycan
binding site.
*
This work was supported in part by a grant from NovaDx, Inc.
and by United States Public Health Service Grant AG07996. The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
``advertisement'' in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biology,
0322, University of California, San Diego, 9500 Gilman Dr., La Jolla,
CA 92093-0322. Tel.: 619-534-2120; Fax: 619-534-1492.
1
The abbreviations used are: DMEM, Dulbecco's
modified Eagle's medium; YKL-39, the 39-kDa human chondrocyte protein
with the N terminus YKL; YKL-40, the 40-kDa human chondrocyte protein
with the N terminus YKL (also called HC gp-39; see Ref. 4); PAGE,
polyacrylamide gel electrophoresis.
2
When purified YKL-40 is dried in preparation for
loading onto a gel, it gives variable amounts of dimeric YKL-40 (data
not shown). This accounts for the 80-kDa band seen in Fig. 1
(inset), a band that was not seen in the SDS-PAGE of these
fractions when the drying step was omitted.
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. P. Bussink, D. Speijer, J. M. F. G. Aerts, and R. G. Boot Evolution of Mammalian Chitinase(-Like) Members of Family 18 Glycosyl Hydrolases Genetics, October 1, 2007; 177(2): 959 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Nair, K. J. Guild, and D. Artis Novel Effector Molecules in Type 2 Inflammation: Lessons Drawn from Helminth Infection and Allergy J. Immunol., August 1, 2006; 177(3): 1393 - 1399. [Full Text] [PDF] |
||||
![]() |
H. F. Bigg, R. Wait, A. D. Rowan, and T. E. Cawston The Mammalian Chitinase-like Lectin, YKL-40, Binds Specifically to Type I Collagen and Modulates the Rate of Type I Collagen Fibril Formation J. Biol. Chem., July 28, 2006; 281(30): 21082 - 21095. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kzhyshkowska, S. Mamidi, A. Gratchev, E. Kremmer, C. Schmuttermaier, L. Krusell, G. Haus, J. Utikal, K. Schledzewski, J. Scholtze, et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway Blood, April 15, 2006; 107(8): 3221 - 3228. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. V. Jensen, J. S. Johansen, and P. A. Price High Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4423 - 4434. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Fusetti, T. Pijning, K. H. Kalk, E. Bos, and B. W. Dijkstra Crystal Structure and Carbohydrate-binding Properties of the Human Cartilage Glycoprotein-39 J. Biol. Chem., September 26, 2003; 278(39): 37753 - 37760. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Houston, A. D. Recklies, J. C. Krupa, and D. M. F. van Aalten Structure and Ligand-induced Conformational Change of the 39-kDa Glycoprotein from Human Articular Chondrocytes J. Biol. Chem., August 8, 2003; 278(32): 30206 - 30212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Cope Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis Rheumatology, June 1, 2003; 42(6): 716 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Tanwar, M. R. Gilbert, and E. C. Holland Gene Expression Microarray Analysis Reveals YKL-40 to Be a Potential Serum Marker for Malignant Character in Human Glioma Cancer Res., August 1, 2002; 62(15): 4364 - 4368. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ostergaard, J. S. Johansen, T. Benfield, P. A. Price, and J. D. Lundgren YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis Clin. Vaccine Immunol., May 1, 2002; 9(3): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. Varela, A. S. Llera, R. A. Mariuzza, and J. Tormo Crystal Structure of Imaginal Disc Growth Factor-2. A MEMBER OF A NEW FAMILY OF GROWTH-PROMOTING GLYCOPROTEINS FROM DROSOPHILA MELANOGASTER J. Biol. Chem., April 5, 2002; 277(15): 13229 - 13236. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Harbord, M. Novelli, B. Canas, D. Power, C. Davis, J. Godovac-Zimmermann, J. Roes, and A. W. Segal Ym1 Is a Neutrophil Granule Protein That Crystallizes in p47phox-deficient Mice J. Biol. Chem., February 8, 2002; 277(7): 5468 - 5475. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Patil, F. C. Hall, S. Drover, D. R. Spurrell, E. Bos, A. P. Cope, G. Sonderstrup, and E. D. Mellins Autoantigenic HCgp39 Epitopes Are Presented by the HLA-DM-Dependent Presentation Pathway in Human B Cells J. Immunol., January 1, 2001; 166(1): 33 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Sekine, K Masuko-Hongo, T Matsui, H Asahara, M Takigawa, K Nishioka, and T Kato Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis Ann Rheum Dis, January 1, 2001; 60(1): 49 - 54. [Abstract] [Full Text] |
||||
![]() |
K Vos, P Steenbakkers, A M M Miltenburg, E Bos, M W van den Heuvel, R A van Hogezand, R R P de Vries, F C Breedveld, and A M H Boots Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis, July 1, 2000; 59(7): 544 - 548. [Abstract] [Full Text] |
||||
![]() |
J. M. Vinetz, J. G. Valenzuela, C. A. Specht, L. Aravind, R. C. Langer, J. M. C. Ribeiro, and D. C. Kaslow Chitinases of the Avian Malaria Parasite Plasmodium gallinaceum, a Class of Enzymes Necessary for Parasite Invasion of the Mosquito Midgut J. Biol. Chem., March 31, 2000; 275(14): 10331 - 10341. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Guo, R. S. Johnson, and J. C. L. Schuh Biochemical Characterization of Endogenously Formed Eosinophilic Crystals in the Lungs of Mice J. Biol. Chem., March 10, 2000; 275(11): 8032 - 8037. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takahashi, Y. Sendai, Y. Matsuda, H. Hoshi, M. Hiroi, and Y. Araki Mouse Oviduct-Specific Glycoprotein Gene: Genomic Organization and Structure of the 5'-Flanking Regulatory Region Biol Reprod, February 1, 2000; 62(2): 217 - 226. [Abstract] [Full Text] |
||||
![]() |
M. Owhashi, H. Arita, and N. Hayai Identification of a Novel Eosinophil Chemotactic Cytokine (ECF-L) as a Chitinase Family Protein J. Biol. Chem., January 14, 2000; 275(2): 1279 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Tjoelker, L. Gosting, S. Frey, C. L. Hunter, H. Le Trong, B. Steiner, H. Brammer, and P. W. Gray Structural and Functional Definition of the Human Chitinase Chitin-binding Domain J. Biol. Chem., January 7, 2000; 275(1): 514 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Kawamura, T Shibata, O Saget, D Peel, and P. Bryant A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells Development, January 1, 1999; 126(2): 211 - 219. [Abstract] [PDF] |
||||
![]() |
R. G. Boot, G. H. Renkema, M. Verhoek, A. Strijland, J. Bliek, T. M. A. M. O. de Meulemeester, M. M. A. M. Mannens, and J. M. F. G. Aerts The Human Chitotriosidase Gene. NATURE OF INHERITED ENZYME DEFICIENCY J. Biol. Chem., October 2, 1998; 273(40): 25680 - 25685. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. O. Keyhani, L.-X. Wang, Y. C. Lee, and S. Roseman The Chitin Disaccharide, N,N'-Diacetylchitobiose, Is Catabolized by Escherichia coli and Is Transported/Phosphorylated by the Phosphoenolpyruvate:Glycose Phosphotransferase System J. Biol. Chem., October 13, 2000; 275(42): 33084 - 33090. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Boot, E. F. C. Blommaart, E. Swart, K. Ghauharali-van der Vlugt, N. Bijl, C. Moe, A. Place, and J. M. F. G. Aerts Identification of a Novel Acidic Mammalian Chitinase Distinct from Chitotriosidase J. Biol. Chem., February 23, 2001; 276(9): 6770 - 6778. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||